Post by Jim Shi
Founder, LeaseMind/AACII, China–Australia regulatory & clinical bridge,life-sciences investor/pharmaceutical scientist with first-author research on Astilbin/a compound later included in the 2020 Chinese Pharmacopoeia.
🇦🇺 AU Biotech Weekly | July 2026 📈 52 global M&A deals in H1 (vs. 30 last year) — China assets re-priced. Novartis buys Myricx Bio for US$1.5B. Amtagvi® + OncoSil™ hit ARTG. Aikenhead Centre lands A$206M. The signal: Australia’s CTN pathway is becoming the de-risking gateway for cross-border biopharma value. Full report 👇 by AACII — Australia AI Clinical Intelligence 📩 [email protected]
